In Interim Results ts 2016 - September 2016 Midatech Pharma plc - PowerPoint PPT Presentation

Aug 18, 2022 •281 likes •586 views

In Interim Results ts 2016 - September 2016 Midatech Pharma plc Disclaimer THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR

In Interim Results ts 2016 - September 2016 Midatech Pharma plc

Recommend

2010 Interim Results 2010 Interim Results 12 August 2010 2010 Interim Results 2010 Interim

2010 Interim Results 2010 Interim Results 12 August 2010 2010 Interim Results 2010 Interim Results Terry Davis Group Managing Director Highlights of 2010 Interim Result 1. Strong result with double-digit growth in EBIT, NPAT and EPS EBIT up

558 views • 18 slides

Briefing on Interim F Briefing on Interim F inancial Results inancial Results Briefing on

Briefing on Interim F Briefing on Interim F inancial Results inancial Results Briefing on Interim F Briefing on Interim F inancial Results inancial Results Briefing on Interim F Briefing on Interim F inancial Results inancial Results and

363 views • 19 slides

Interim RESULTS 2019 | INTERIM RESULTS 2019 Agenda Interim Results 2019 Company and market

Interim RESULTS 2019 | INTERIM RESULTS 2019 Agenda Interim Results 2019 Company and market overview Financial overview Retail portfolio overview Outlook INTERIM RESULTS 2019 | AGENDA (2) Company and market overview HADLEY DEAN CEO

863 views • 49 slides

2004 Interim Results Presentation Interim Results Presentation 2004 2004 Interim Results

2004 Interim Results Presentation Interim Results Presentation 2004 2004 Interim Results Presentation August 10, 2004 Asahi Breweries, Ltd. URL http://www.asahibeer.co.jp/english/index.html 2004 Interim Results Overview (consolidated)

479 views • 14 slides

2012 Interim Results 2012 Interim Results Ken Hanna Chairman 2012 Interim Results Financial

2012 Interim Results 2012 Interim Results Ken Hanna Chairman 2012 Interim Results Financial Review Angus Cockburn Finance Director 2012 Interim Results 2012 2011 Movement m m As reported Underlying Revenue 734 637 15% 16%

400 views • 23 slides

INTERIM RESULTS 2019 Interim Results 2019 AGENDA Introduction David Squires CEO 2019 Interim

INTERIM RESULTS 2019 Interim Results 2019 AGENDA Introduction David Squires CEO 2019 Interim Results Bindi Foyle FD Markets & Outlook David Squires CEO Interim Results 2019 H1 2019 HIGHLIGHTS Sales and profit growth despite 737

563 views • 54 slides

Interim results for the 6 months to 30 June 2015 SEPTEMBER 2015 Interim Results September 2015

Interim Results September 2015 Interim results for the 6 months to 30 June 2015 SEPTEMBER 2015 Interim Results September 2015 CELLO INTRODUCTION We supply marketing advisory services primarily in the pharmaceutical sector Global

420 views • 27 slides

Financial Results Thursday 21 August 2014 Presentation Team Sportech PLC 2014 Interim Results

Sportech PLC 2012 Interim Results 2014 Interim Financial Results Thursday 21 August 2014 Presentation Team Sportech PLC 2014 Interim Results Sportech PLC 2012 Interim Results Roger Withers Chairman Ian Penrose Chief Executive Cliff Baty

648 views • 29 slides

INTERIM RESULTS PRESENTATION 6 MONTHS ENDED 30 JUNE 2016 September 2016 INTERIM RESULTS

INTERIM RESULTS PRESENTATION 6 MONTHS ENDED 30 JUNE 2016 September 2016 INTERIM RESULTS PRESENTATION Contents 1 First Half review 2 Full Year outlook 3 Financial Appendices 2 1. 2016 FIRST HALF REVIEW 2016 FIRST HALF REVIEW We go to

714 views • 38 slides

2019 INTERIM RESULTS AGENDA 1 Iain Williamson, Interim Group H1 2019 OVERVIEW CEO 2 2019

2019 INTERIM RESULTS AGENDA 1 Iain Williamson, Interim Group H1 2019 OVERVIEW CEO 2 2019 INTERIM RESULTS Casper Troskie, Group CFO 3 Iain Williamson, Interim Group CONCLUDING REMARKS CEO 4 Q&A 2 H1 2019 OVERVIEW Strong financial

356 views • 33 slides

Results Meeting Results Meeting for for the Interim Period ended the Interim Period ended

Results Meeting Results Meeting for for the Interim Period ended the Interim Period ended September 30, 2006 September 30, 2006 (April 1, 2006 September 30, 2006) September 30, 2006) (April 1, 2006 Table of Contents Table of

461 views • 18 slides

Second Interim Management Statement 2013 Second Interim Management Statement 2013 Second Interim

Second Interim Management Statement 2013 24 OCTOBER 2013 Second Interim Management Statement 2013 Second Interim Management Statement 2013 Second Interim Management Statement 2013 Heinz Eigner Graham Buttenshaw Bob Katsiouleris Michael

388 views • 13 slides

First Interim Management Statement 2013 First Interim Management Statement 2013 First Interim

First Interim Management Statement 2013 24 APRIL 2012 First Interim Management Statement 2013 First Interim Management Statement 2013 First Interim Management Statement 2013 Greg McMillan Heinz Eigner Chief Operating Officer Chief Financial

186 views • 15 slides

2017 ADAPT IT INTERIM RESULTS PRESENTATION 2017 BUSINESS OVERVIEW 1 ADAPT IT INTERIM RESULTS

INTERIM RESULTS PRESENTATION for the six months ended 31 December 2017 ADAPT IT INTERIM RESULTS PRESENTATION 2017 BUSINESS OVERVIEW 1 ADAPT IT INTERIM RESULTS PRESENTATION 2017 ABOUT ADAPT IT VISION Education | Manufacturing | Financial

558 views • 29 slides

Interim Results 2017 3 August 2017 INMARSAT > Interim Results 2017 Mid-year review Rupert

INMARSAT > Interim Results 2017 Interim Results 2017 3 August 2017 INMARSAT > Interim Results 2017 Mid-year review Rupert Pearce Chief Executive Officer Market context Structural Change Demand Side Supply Side Inmarsat Will

636 views • 31 slides

ITV plc Interim Results 2009 6 th August 2009 Interim Results 2009 0 Overview Michael Grade

ITV plc Interim Results 2009 6 th August 2009 Interim Results 2009 0 Overview Michael Grade Interim Results 2009 1 Agenda Overview Michael Grade Financial review Ian Griffiths Operating review and current trading John

720 views • 43 slides

Activating the Redeye pre-ASCO seminar immune system to Dr. Erik D Wiklund - CBO Company

Activating the Redeye pre-ASCO seminar immune system to Dr. Erik D Wiklund - CBO Company presentation fight cancer 28 May 2019 August 2018 IMPORTANT NOTICE AND DISCLAIMER This report contains certain forward-looking statements based on

877 views • 14 slides

Small Cell Carcinoma of the Ovary: Report of a Case with Unusual and Aggressive Presentation

Case Report Middle East Journal of Cancer; July 2017; 8(3): 161-165 Small Cell Carcinoma of the Ovary: Report of a Case with Unusual and Aggressive Presentation Fatemeh Sadat Najib* , ***, Mojdeh Momtahan*, Maral Mokhtari**, Shaghayegh Moradi

608 views • 5 slides

computerized tomographic scan confirmed bilateral with dermatomyositis, there was a high incidence

RESEARCH LETTER D ERMATOMYOSITIS AS THE I NITIAL P RESENTATION OF O VARIAN C ANCER Lai-Wan Chao, Lin-Hung Wei 1 * Departments of Obstetrics and Gynecology, and 1 Oncology, National Taiwan University Hospital and National Taiwan University

174 views • 3 slides

ASCOs Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes

ASCOs Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes and implementation of a pharmacist- managed oral chemotherapy follow-up program Presenters Name: Sonja Jacobsen, PharmD Firas Shadad, MD

506 views • 22 slides

neoplasia and intraductal papillary mucinous neoplasm Xianzhong Ding, Brandon Trac, and Xiuzhen

Expression of GRP78 protein is increased in pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm Xianzhong Ding, Brandon Trac, and Xiuzhen Duan Department of Pathology Loyola

133 views • 12 slides

CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY JANUARY 2020 NASDAQ: XOMA 1

CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY JANUARY 2020 NASDAQ: XOMA 1 DISCLAIMERS Certain statements in this presentation are forward-looking Potential risks to XOMA meeting these expectations are statements within the meaning

825 views • 28 slides

September 2019 1 Safe Harbor Statement This presentation contains forward-looking statements

INODIFTAGENE Gene Therapy for Bladder Cancer September 2019 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of U.S. federal securities laws and Israeli securities laws that involve risks and

297 views • 16 slides

Genomics in science and clinical care Frdrique Nowak Institut National du Cancer October

Genomics in science and clinical care Frdrique Nowak Institut National du Cancer October 8, 2012 I nstitut national du cancer (I NCa) The French National Cancer Institute is a health and science agency dedicated to oncology.

204 views • 19 slides